臨床外科78巻12号

2023年11月発行

特集 胃癌に対するconversion surgery—Stage Ⅳでも治したい！

総論

腫瘍内科医からみたconversion surgery

著者： 中山厳馬¹

所属機関： ¹がん研究会有明病院消化器化学療法科

ページ範囲：P.1333 - P.1338

文献概要

【ポイント】
◆診断時切除不能胃癌の化学療法奏効例で原発切除を受けず，化学療法を継続した症例の生存期間中央値は27.9か月であった．
◆Conversion手術を受けた症例の再発率は高率であったが，再発例は全例化学療法を施行されていた．
◆手術と化学療法を組み合わせて，長期生存のチャンスを高めるように外科医と腫瘍内科医が力を合わせることが最も肝要である．

参考文献

1）Boku N, Yamamoto S, Fukuda H, et al：Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer：a randomised phase 3 study. Lancet Oncol 10：1063-1069, 2009

2）Koizumi W, Narahara H, Hara T, et al：S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer（SPIRITS trial）：a phase Ⅲ trial. Lancet Oncol 9：215-221, 2008

3）Van Cutsem E, Moiseyenko VM, Tjulandin S, et al：Phase Ⅲ study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer：a report of the V325 study group. J Clin Oncol 24：4991-4997, 2006

4）Ajani JA, Rodriguez W, Bodoky G, et al：Multicenter phase Ⅲ comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study：The FLAGS trial. J Clin Oncol 28：1547-1553, 2010

5）Cunningham D, Starling N, Rao S, et al：Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer. N Engl J Med 358：36-46, 2008

6）Janjigian YY, Shitara K, Moehler M, et al：First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma（CheckMate 649）：a randomised, open-label, phase 3 trial. Lancet 398：27-40, 2021

7）Kang YK, Chen LT, Ryu MH, et al：Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer（ATTRACTION-4）：a randomised, multicentre, double-blind, placebo-contr. Lancet Oncol 23：234-247, 2022

8）Bang YJ, Van Cutsem E, Feyereislova A, et al：Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer（ToGA）：A phase 3, open-label, randomised controlled trial. Lancet［Internet］. 376：687-697, 2010

9）Fujitani K, Yang HK, Mizusawa J, et al：Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor（REGATTA）：a phase 3, randomised controlled trial. Lancet Oncol 17：309-318, 2016

10）Hironaka S, Ueda S, Yasui H, et al：Randomized, open-label, phase Ⅲ study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum：WJOG 4007 tria. J Clin Oncol 31：4438-4444, 2013

11）Shitara K, Doi T, Dvorkin M, et al：Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer（TAGS）：a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 19：1437-1448, 2018

12）Shitara K, Bang YJ, Iwasa S, et al：Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N Engl J Med 382：2419-2430, 2020

13）Nakayama I, Takahari D, Shimozaki K, et al：Clinical progress in inoperable or recurrent advanced gastric cancer treatment from 1004 single institute experiences between 2007 and 2018. Oncologist 27：e506-e517, 2022

14）Yamaguchi K, Yoshida K, Tanahashi T：The long-term survival of stage Ⅳ gastric cancer patients with conversion therapy. Gastric Cancer 21：315-323, 2018

15）Chen G, Yuan S, Nie R, et al：Surgical outcome and long-term survival of conversion surgery for advanced gastric cancer. Ann Surg Oncol 27：4250-4260, 2020

16）Shitara K, Ajani JA, Moehler M, et al：Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer. Nature 603：942-948, 2022